MedPath

Efficacy of dulaglutide after switching from incretin related drugs in patients with type 2 diabetes

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000042812
Lead Sponsor
Edogawa Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
101
Inclusion Criteria

Not provided

Exclusion Criteria

Subjects in whom antidiabetic agents other than GLP-1 RAs or DPP-4 inhibitors were changed during the observation period

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HbA1c and body weight at 6 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath